Aller au contenu

Cris Bergerot, PhD

@crisbergerot.bsky.social did:plc:c7uckvugvdgto5clyo7p63uh

Advancing oncology care through research, innovation, and multidisciplinary collaboration. Passionate about patient-centered solutions, PROs, HRQOL, and evidence-based practices, w a focus on #GUOnc, #GeriOnc & #PallOnc #ASCO25 FCOI: http://bit.ly/344gKxq

Sur Bluesky depuis le

Abonnés
545
Abonnements
202
Posts
98
Jours dans les classements
0

Résumé

Cris Bergerot, PhD (@crisbergerot.bsky.social) est sur Bluesky depuis le 28 novembre 2024. Le compte a 545 abonnés, suit 202 comptes et a publié 98 posts.

Présence dans les classements

Les meilleurs jours où les posts de ce compte sont entrés dans le top quotidien de Debya.

Ce compte n’est encore apparu dans aucun classement quotidien.

Posts aimés récemment

J’aime publics du réseau Bluesky.

  • American Society of Clinical Oncology@ascocancer.bsky.social

    And the answer was ... D! Erdafitinib causes ocular toxicity; a baseline ophthalmic exam is required. Did you get it right? Let us know in the comments! Subscribe to ASCO-SEP® today: bit.ly/47OmqN7 ASCO members get 20% off; additional discounts available.

    Voir le post
  • American Society of Clinical Oncology@ascocancer.bsky.social

    New Living Guideline: Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I to III Breast Cancer. The new Living Guideline covers the use of medical therapies for stage I-III hormone receptor-positive, HER2-negative breast cancer. Learn more: https://bit.ly/4spJjjv

    Voir le post
  • American Society of Clinical Oncology@ascocancer.bsky.social

    Dr. Sumanta Pal of @cityofhope.bsky.social and @ryannipp.bsky.social of OU Health Stephenson Cancer Center discuss high-impact research presented at #ASCOQLTY26 on the latest episode of the #ASCODailyNews Podcast: https://bit.ly/4zg53kt

    Voir le post
  • International Kidney Cancer Coalition@ikccorg.bsky.social

    We are proud to continue our partnership with the American Association for Cancer Research (AACR) to support the AACR Scholar-in-Training Award! 🗓️ Application Deadline: 10 November 2026 🔗 Learn more and apply: buff.ly/yx1Y0QV

    Voir le post
  • KidneyCAN@kidneycan.bsky.social

    No two #kidneycancer journeys are the same. Built with KidneyCAN & Eisai, Kompass can help guide you to tailored resources and support that fit where you are today. Explore for yourself at KidneyCancerKompass.com.

    Voir le post

Connectez-vous pour en voir plus

Comptes bloqués

Sur Bluesky, les blocages sont publics.

Ce compte ne bloque personne.